<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03833700</url>
  </required_header>
  <id_info>
    <org_study_id>E7386-J081-103</org_study_id>
    <nct_id>NCT03833700</nct_id>
  </id_info>
  <brief_title>A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)</brief_title>
  <official_title>An Open-label Phase 1 Study of E7386 in Subjects With Advanced Solid Tumor Including Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of E7386 in
      participants with solid tumor including CRC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in 2 parts: dose escalation part and expansion part. The study
      will include Pre-treatment Phase, Treatment Phase, and Extension Phase (in expansion part
      only).

      Eligible participants from Pre-Treatment Phase (screening period) will enter into the
      Treatment Phase to receive E7386. After Treatment Phase, participants will be followed in
      follow-up period of Extension Phase (in expansion part only).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline up to Cycle 1 (Cycle length is equal to [=] 28 days)</time_frame>
    <description>DLT will be defined as any of the events that are considered by the investigator to be at least possibly related to therapy with the study medication. Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment (approximately 2.5 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for E7386</measure>
    <time_frame>Cycle 1 Day 1: 0-12 hours; Cycle 1 Day 8: 0-12 hours; Cycle 2-6, Day 1: Pre-dose (Cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7386</measure>
    <time_frame>Cycle 1 Day 1: 0-12 hours; Cycle 1 Day 8: 0-12 hours; Cycle 2-6, Day 1: Pre-dose (Cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC: Area Under the Plasma Concentration Versus Time Curve for E7386</measure>
    <time_frame>Cycle 1 Day 1: 0-12 hours; Cycle 1 Day 8: 0-12 hours; Cycle 2-6, Day 1: Pre-dose (Cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent Total Body Clearance for E7386</measure>
    <time_frame>Cycle 1 Day 1: 0-12 hours; Cycle 1 Day 8: 0-12 hours; Cycle 2-6, Day 1: Pre-dose (Cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F: Apparent Volume of Distribution for E7386</measure>
    <time_frame>Cycle 1 Day 1: 0-12 hours; Cycle 1 Day 8: 0-12 hours; Cycle 2-6, Day 1: Pre-dose (Cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Best Overall Response (BOR)</measure>
    <time_frame>From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2.5 years)</time_frame>
    <description>BOR is defined as complete response (CR), partial response (PR), stable disease (SD), PD, and not evaluable (NE), where SD has to be achieved at greater than or equal to (&gt;=) 7 weeks after the first dose. The BOR will be assessed by investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2.5 years)</time_frame>
    <description>The ORR is defined as the percentage of participants with a BOR of CR or PR. The ORR will be assessed by investigator based on RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2.5 years)</time_frame>
    <description>DCR is defined as the percentage of participants with a BOR of CR, PR, or SD. The DCR will be assessed by investigator based on RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2.5 years)</time_frame>
    <description>The CBR is defined as the percentage of participants with a BOR of CR, PR, or durable SD (duration of SD &gt;=23 weeks). The CBR will be assessed by investigator based on RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From first dose of study drug until PD, or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
    <description>PFS is defined as the time from the date of the first dose to the date of the first documentation of confirmed PD or death, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Solid Neoplasms</condition>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Part: E7386</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E7386 10, 15, 20 mg (milligram) or more, tablets, orally, twice daily, in 28-days treatment cycle until disease progression (PD), development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E7386, tablets, orally, twice daily in 28-days treatment cycle until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. The highest dose of E7386 which is deemed tolerable or the optimal dose based on PK or PD analysis in dose escalation part will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7386</intervention_name>
    <description>E7386, tablets, orally.</description>
    <arm_group_label>Dose Escalation Part: E7386</arm_group_label>
    <arm_group_label>Expansion Part</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants must have any of the following tumor types:

               1. Dose Escalation Part: Participants with advanced, unresectable, or recurrent
                  solid tumor including CRC for which no alternative standard therapy or no
                  effective therapy exists

               2. Expansion Part: Participants with advanced, unresectable, or recurrent CRC for
                  which no alternative standard therapy or no effective therapy exists

          2. Participants with CRC must consent to biopsy and submit the archival tumor tissue if
             it is stored

          3. Life expectancy of &gt;=12 weeks

          4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          5. All AEs due to previous anti-cancer therapy have either returned to Grade 0-1 except
             for alopecia and Grade 2 peripheral neuropathy (renal/bone marrow/liver function
             should meet the inclusion criteria)

          6. Adequate washout period before study drug administration:

               1. Chemotherapy and radiotherapy: 3 weeks or more

               2. Any therapy with antibody: 4 weeks or more

               3. Any investigational drug or device: 4 weeks or more

               4. Blood/platelet transfusion or Granulocyte-colony stimulating factor (G-CSF): 2
                  weeks or more

          7. Adequate renal, bone marrow, liver function, and serum mineral level

          8. At least one measurable lesion based on RECIST 1.1

        Exclusion Criteria:

          1. Known to be human immunodeficiency virus (HIV) positive

          2. Active infection requiring systemic treatment

          3. Diagnosed with meningeal carcinomatosis

          4. Participants with brain or subdural metastases are not eligible, unless they have
             completed local therapy and have discontinued the use of corticosteroids for this
             indication for at least 4 weeks before starting treatment in this study. Any signs
             (example: radiologic) or symptoms of brain metastases must be stable for at least 4
             weeks before starting study treatment

          5. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring
             active treatment, including the use of oxygen

          6. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled
             gastrointestinal condition (example: nausea, diarrhea, or vomiting) that might impair
             the bioavailability of E7386

          7. Any of bone disease/conditions as follows;

               1. Osteoporosis with T-score less than (&lt;) -2.5 by Dual energy X-ray absorptiometry
                  (DXA) scan

               2. Fasting Beta-isomerised carboxy terminal telopeptide of type I collagen (Î²-CTX)
                  (serum) greater than (&gt;) 1000 picograms per milliliter (pg/mL)

               3. Osteomalacia

               4. Symptomatic hypercalcemia requiring bisphosphonate therapy

               5. History of any fracture within 6 months prior to starting study drug

               6. Any condition requiring orthopedic intervention

               7. In spite of bone metastases, lack of treatment with a bisphosphonate or denosumab
                  (participants with previous solitary bone lesions controlled with radiotherapy
                  are eligible)

          8. History of active malignancy (except for original disease, or definitively treated
             melanoma in-situ, basal or squamous cell carcinoma of the skin, carcinoma in-situ of
             the bladder or cervix, or early stage gastric/colorectal cancer) within the past 24
             months prior to the first dose of study drug

          9. Prior treatment with E7386

         10. 25-Hydroxyvitamin D levels less than 10 ng/mL (nanogram per milliliter)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Inquiry Service</last_name>
    <email>eisai-chiken_hotline@hhc.eisai.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Chuo Ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>February 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>E7386</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

